Chapter review

Fitzgerald PMHNP board review. ch08. Mood Disorders. This is drive 4 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. Bipolar and related disorders: criteria, mixed features, rapid cycling, mania vs hypomania. Topic. Table 8-1: Bipolar Genetics and Relapse. Bottom Line Summary. * **Bipolar I Lifetime Prevalence**: Affects 1.5% of the population with an equal gender ratio between men and women, whereas **Bipolar II** affects 1.2% with a higher prevalence in women, bringing the overall bipolar spectrum prevalence up to 6%. * **Age of Onset**: The mean age of onset for bipolar disorder is 21 to 24 years, with an incidence in children and adolescents of 1%. * **Genetic Risk & Twin Concordance**: First-degree relatives of individuals with bipolar disorder carry a 5% to 10% risk, while monozygotic twin concordance reaches 40% to 50%. * **Relapse Dynamics**: Following a single manic episode, 90% of individuals experience recurrent mood episodes, and 40% to 50% of **Bipolar I** patients suffer a second manic episode within 2 years. * **Depression Sequence**: Up to 60% of manic episodes occur immediately before a major depressive episode, and 5% to 10% of patients initially diagnosed with major depressive disorder experience a manic episode 6 to 10 years after their first depression. * **Environmental Triggers**: Cannabis use and substance use disorders directly trigger the onset of a first manic episode and drive clinical relapses. * **Lock and Key Etiology**: Bipolar episodes are conceptualized as external environmental stressors acting as a key upon a genetically and biochemically predisposed individual to unlock mania. * **Psychoeducation Protection**: Structured individual or group psychoeducation regarding sleep hygiene, early warning signs, and medication adherence reduces bipolar relapse rates by 25% to 30%. Detailed Leaf Review: Table 8-1 Bipolar Genetics and Relapse. Epidemiologic Prevalence and Gender Patterns. * Major depressive disorder affects 12% of the population with a two-to-one female-to-male ratio, and its prevalence in young adults aged 18 to 29 is three times higher than in adults over age 60. * In contrast, the bipolar spectrum reaches up to 6% total prevalence. Within this spectrum, **Bipolar I** carries a 1.5% lifetime prevalence with equal rates in men and women, whereas **Bipolar II** carries a 1.2% lifetime prevalence and affects women more frequently than men. * Both conditions represent illnesses of younger populations, with major depression presenting at a mean age of 20 to 35 years and bipolar disorder presenting slightly earlier at a mean age of 21 to 24 years. Genetic Heritability and Risk. * First-degree relatives of individuals with major depressive disorder have a 2 to 4 times higher risk of depression than the general population, reflecting a 40% heritability rate. * First-degree relatives of individuals with bipolar disorder face a 5% to 10% lifetime risk. * Genetic concordance rises dramatically in monozygotic twins, who share a 40% to 50% risk for bipolar disorder, demonstrating a powerful genetic substrate. Etiology and Environmental Relapse Drivers. * Bipolar disorder etiology follows a lock and key model where genetic and biochemical vulnerability represents the lock, and acute external environmental stressors or life pressures act as the key that unlocks a manic episode. * Cannabis and substance use disorders are the primary environmental drivers that trigger initial manic conversion and cause subsequent mood relapses. * Medical inpatients face a 15% elevated risk for major depression compared to the general population, and non-mood comorbidities such as ADHD, anxiety, PTSD, and substance use frequently co-occur across both depressive and bipolar spectrums. Natural History, Recurrence, and Progression. * Bipolar disorder is a chronic, recurring illness. A single manic episode carries a 90% lifetime probability of future recurrent mood episodes. * Recurrence happens rapidly, with 40% to 50% of **Bipolar I** patients experiencing a second manic episode within 2 years of their first. * Manic episodes frequently transition directly into depression, with 60% of manic episodes occurring immediately prior to a major depressive episode. * Diagnostic conversion is common over time. Between 5% and 10% of patients presenting with unipolar major depressive disorder experience their first manic episode 6 to 10 years after their initial depressive presentation. * Multiple unipolar or bipolar mood episodes lead to neuroprogressive structural brain changes, cognitive impairment, and decreased treatment responsiveness during subsequent acute episodes. Signposted Board Pearls and Traps. * **First-line**: **Lithium** is first-line pharmacotherapy for classic euphoric mania and long-term maintenance, and **valproate** is first-line for dysphoric mania, mixed features, or comorbid substance use disorder. * **Safety alert**: Antidepressant monotherapy in bipolar disorder is strictly contraindicated because it can precipitate manic conversion, rapid cycling, or mixed states. * **Board trap**: Mistaking a first manic episode induced by an antidepressant as simple unipolar drug toxicity. If full manic criteria persist beyond the expected physiological effect of the antidepressant, the patient meets criteria for a primary **Bipolar I** diagnosis. * **First-line**: Integrate structured individual or group psychoeducation focused on regular sleep-wake rhythms and early relapse sign identification, which independently reduces relapse rates by 25% to 30%. * **Safety alert**: **Lithium** and **clozapine** are the only two psychotropic medications with proven independent anti-suicide efficacy. Fitzgerald Sample Test Questions. Question 1. Which of the following statements is false regarding the diagnosis of major depression? A) More likely to occur in men than women B) Higher prevalence for whites than blacks C) Lifetime prevalence is 12% D) Risk factors include genetics and low education Pause. Answer. A. * **Why It Is Correct**: Major depressive disorder is twice as likely to occur in women as in men. Statement A claims it is more likely in men, making it false. * **Why Other Choices Fail**: * **B**: True. Epidemiologic data shows higher reported prevalence in white populations compared to Black populations. * **C**: True. Lifetime prevalence for major depressive disorder is established at 12%. * **D**: True. Family history/genetics and lower socioeconomic/educational status are documented risk factors for major depression. Question 2. Jeremy, a 36-year-old married attorney, was referred by his primary care provider for a consultation regarding his depression. He relates problems with what he calls minor depression and mood swings for at least 15 years. He denies ever having any suicidal ideation, hospitalization, or legal difficulty. On the Mood Disorder Questionnaire, he checks four items positive and three as possibly positive. Which disorder most likely fits his symptoms? A) Bipolar I disorder B) Bipolar II disorder C) Cyclothymic disorder D) Dysthymia Pause. Answer. C. * **Why It Is Correct**: Cyclothymic disorder is a chronic mood disturbance lasting at least 2 years in adults involving numerous periods of hypomanic symptoms and depressive symptoms that do not meet full criteria for major depressive or hypomanic episodes. Jeremy's 15-year history of minor mood swings without hospitalization, legal trouble, or full manic episodes fits cyclothymia. * **Why Other Choices Fail**: * **A**: Bipolar I disorder requires at least 1 full manic episode causing severe functional disruption, legal issues, or hospitalization, which Jeremy denies. * **B**: Bipolar II disorder requires at least 1 major depressive episode and 1 distinct hypomanic episode, whereas Jeremy reports minor depression and low-grade fluctuations. * **D**: Dysthymia consists of chronic low-grade depression without hypomanic swings or elevated periods. Question 3. The patient with bipolar disorder who is most likely to be misdiagnosed as having unipolar depression most likely has: A) Dysthymia B) Bipolar II disorder C) Bipolar I disorder D) Cyclothymic disorder Pause. Answer. B. * **Why It Is Correct**: Patients with **Bipolar II disorder** seek psychiatric care during painful major depressive episodes and rarely report past hypomanic episodes because hypomania feels pleasant and productive. Consequently, clinicians frequently misdiagnose Bipolar II as unipolar depression. * **Why Other Choices Fail**: * **A**: Dysthymia is a unipolar depressive disorder without hypomanic or manic history. * **C**: Bipolar I disorder features overt manic episodes with marked functional disruption, making it easily distinguishable from unipolar depression. * **D**: Cyclothymic disorder involves low-grade mood shifts that do not meet criteria for major depressive episodes, so patients rarely present with severe unipolar depressive complaints. Question 4. There is positive evidence that the use of lithium by a breastfeeding woman can pose a risk to the infant. This medication meets Hale's lactation risk category: A) L1 B) L2 C) L3 D) L4 Pause. Answer. D. * **Why It Is Correct**: Lithium is classified under Hale's lactation risk category L4 (hazardous), meaning there is positive evidence of risk to the infant from fluid and electrolyte shifts and lithium toxicity. It is contraindicated during breastfeeding. * **Why Other Choices Fail**: * **A**: L1 represents safest medications with no demonstrated risk in infant studies. * **B**: L2 represents safer medications studied in a limited number of breastfeeding women without risk. * **C**: L3 represents moderately safe medications with minimal risk. Question 5. Mr. Cooper is treated for bipolar disorder with lithium carbonate. His last lithium level was 0.7 mEq/L. Which of the following is not a risk factor for developing lithium toxicity? A) Ibuprofen 600 mg daily for joint pain B) Addition of lisinopril to blood pressure regimen C) A change in GFR less than 60 mL/min/1.73 m2 D) Addition of prednisone for the management of an acute gout attack Pause. Answer. D. * **Why It Is Correct**: Prednisone is a corticosteroid that does not impair renal excretion or alter sodium balance in a manner that increases serum lithium levels. It is safe regarding lithium toxicity risk. * **Why Other Choices Fail**: * **A**: NSAIDs like ibuprofen reduce renal prostaglandin synthesis and decrease lithium clearance, significantly raising serum lithium concentrations toward toxicity. * **B**: ACE inhibitors like lisinopril reduce glomerular filtration pressure and increase proximal tubular reabsorption of lithium, leading to severe toxicity. * **C**: Renal impairment with a GFR under 60 mL/min reduces renal elimination because lithium is excreted 100% unchanged by the kidneys, increasing toxicity risk. Question 6. Which of the following psychotropic medications used in bipolar disorder does not require initial baseline laboratory testing prior to initiating therapy? A) Carbamazepine B) Lamotrigine C) Valproate D) Lithium Pause. Answer. B. * **Why It Is Correct**: **Lamotrigine** does not require baseline organ-function blood tests before initiation. Its primary safety monitoring relies on clinical inspection for rash and strict slow dose titration to prevent Stevens-Johnson syndrome. * **Why Other Choices Fail**: * **A**: **Carbamazepine** requires baseline CBC, liver function tests, renal function, and HLA-B*1502 screening in Asian populations. * **C**: **Valproate** requires baseline LFTs, CBC with platelets, and pregnancy testing. * **D**: **Lithium** requires comprehensive baseline renal testing, thyroid function, electrolytes, urinalysis, serum hCG, and EKG. Active Recall Checkpoints. 1. What is the lifetime risk percentage of bipolar disorder for a first-degree relative versus a monozygotic twin? 2. What percentage of patients experience a second manic episode within 2 years of their first manic event? 3. What percentage of patients with initial major depressive disorder convert to a bipolar diagnosis 6 to 10 years later? 4. Which environmental substance is specifically cited as a primary driver of first-episode mania and relapse? 5. How much does structured psychoeducation reduce the risk of bipolar relapse? Next Study Step. Recommend studying **Fitzgerald Chapter 8: Bipolar Pharmacotherapy and Laboratory Monitoring**. * **Why this is the best next step**: Understanding the high genetic heritability and relapse rates of bipolar disorder logically leads to mastering baseline lab protocols, therapeutic drug monitoring, and toxicity prevention for **lithium**, **valproate**, and **carbamazepine**. Next. Topic. Specifiers: Mixed and Rapid Cycling. Bottom Line Summary. * **Rapid cycling criteria**: Defined as **4 or more** distinct major mood episodes (major depressive, manic, or hypomanic) occurring within a **12-month** period. * **Mixed features criteria**: Requires meeting full criteria for a manic, hypomanic, or major depressive episode accompanied by at least **3 symptoms** of the opposing pole during the majority of days. * **First-line pharmacotherapy**: Divalproex (valproate) or second-generation antipsychotics (such as quetiapine, olanzapine, or lurasidone) are **first-line** for mixed features and rapid cycling. * **Lithium vs valproate selection**: Lithium is **first-line** for classic euphoric mania, whereas valproate is **first-line** for dysphoric mania, mixed features, rapid cycling, traumatic brain injury, and comorbid substance use disorders. * **Antidepressant contraindication**: Antidepressant monotherapy is strictly contraindicated in bipolar disorder with mixed features or rapid cycling because it accelerates cycle frequency, worsens agitation, and increases suicide risk. * **Cyclothymia timeline**: Cyclothymic disorder involves chronic mood instability lasting at least **2 years** in adults (1 year in children and adolescents) with subthreshold hypomanic and depressive symptoms present for at least half the time and no symptom-free period exceeding **2 months**. * **Bipolar II diagnostic trap**: Bipolar II disorder requires at least 1 major depressive episode (lasting at least **2 weeks**) and at least 1 hypomanic episode (lasting at least **4 consecutive days**), and is the bipolar disorder most commonly misdiagnosed as unipolar major depressive disorder. Clinical Teaching Narrative. Understanding bipolar specifiers is a top priority for national board certification exams. Test writers frequently build clinical vignettes around subtle presentation differences to evaluate your diagnostic precision and prescribing safety. Rapid Cycling Specifier. The rapid cycling specifier applies to both Bipolar I and Bipolar II disorders. To meet criteria, a patient must experience at least **4 major mood episodes** within a **12-month** period. These episodes can occur in any combination or sequence, including major depressive, manic, or hypomanic episodes. Episodes must be demarcated either by a period of full remission lasting at least **2 months** or by a direct switch to an episode of the opposite polarity. **First-line**: Valproate or carbamazepine is the preferred mood stabilizer for rapid cycling. Second-generation antipsychotics like quetiapine or olanzapine also demonstrate strong efficacy. **Safety alert**: Antidepressant monotherapy must never be used in rapid cycling. Antidepressants frequently act as the driving catalyst behind rapid mood switching and can lock a patient into a continuous cycling pattern. When evaluating a patient with rapid cycling who is currently taking an antidepressant, the immediate clinical priority is to taper and discontinue the antidepressant while optimizing a mood stabilizer. **Board trap**: Do not confuse rapid cycling with ultradian mood swings or borderline personality disorder mood lability. Rapid cycling requires distinct episodes meeting duration thresholds over a 12-month timeline, not hourly or daily emotional shifts. Mixed Features Specifier. The mixed features specifier applies when symptoms of the opposite pole occur during a manic, hypomanic, or depressive episode. During a manic or hypomanic episode, mixed features require the presence of at least **3 depressive symptoms** such as prominent dysphoria, depressed mood, anhedonia, psychomotor retardation, fatigue, worthlessness, or recurrent thoughts of death. Conversely, during a major depressive episode, mixed features require at least **3 manic or hypomanic symptoms** such as elevated or expansive mood, grandiosity, racing thoughts, pressure of speech, increased goal-directed activity, or decreased need for sleep. **First-line**: Valproate or second-generation antipsychotics (quetiapine, olanzapine, lurasidone, ziprasidone) are **first-line** choices for mixed states. **Safety alert**: Patients presenting with mixed features carry the highest immediate suicide risk across the bipolar spectrum. The combination of depressive despair and hopeless ideation paired with manic energy, impulsivity, and psychomotor agitation creates an acute emergency. Immediate safety evaluation and stabilization are required. **Board trap**: Expect test writers to present a patient with severe depression who also exhibits racing thoughts, irritability, and decreased need for sleep. If you mistakenly diagnose unipolar depression and prescribe an SSRI alone, you will trigger severe agitation or mania. Always identify the mixed features and choose a mood stabilizer or atypical antipsychotic. Differential Diagnosis: Bipolar I, Bipolar II, and Cyclothymia. To master board questions on mood disorders, compare how duration, symptom severity, and functional impairment separate these diagnoses: * **Bipolar I Disorder**: Requires at least **1 manic episode** lasting at least **1 week** (or any duration if hospitalization is required). Symptoms include abnormally elevated, expansive, or irritable mood with increased goal-directed activity plus at least **3 DIG FAST symptoms** (4 if mood is only irritable). Causes marked social or occupational impairment, may include psychotic features, and often requires acute hospitalization. * **Bipolar II Disorder**: Requires at least **1 major depressive episode** (lasting at least **2 weeks**) AND at least **1 hypomanic episode** (lasting at least **4 consecutive days**). Hypomania causes an unequivocal change in functioning that is noticeable to others, but it does NOT cause marked impairment, does NOT require hospitalization, and NEVER includes psychotic features. If psychosis or hospitalization occurs, the episode is automatically classified as mania, making the diagnosis Bipolar I. * **Cyclothymic Disorder**: Chronic, fluctuating mood disturbance lasting at least **2 years** in adults (**1 year** in children and adolescents). The patient experiences numerous periods of hypomanic symptoms and periods of depressive symptoms. Symptoms are present for at least half the time, and the individual has not been free of symptoms for more than **2 months** at a time. Full criteria for a major depressive, manic, or hypomanic episode have NEVER been met. Sample Board Practice Questions. Question 1. Jeremy, a 36-year-old married attorney, was referred by his primary care provider for a psychiatric consultation regarding his depression. He relates a history of what he calls minor depression and frequent mood swings for at least 15 years. He denies any history of suicidal ideation, psychiatric hospitalization, or legal difficulties. On the Mood Disorder Questionnaire (MDQ), he checks four items positive and three items as possibly positive. Which of the following diagnoses best fits his clinical presentation? A. Bipolar I disorder B. Bipolar II disorder C. Cyclothymic disorder D. Dysthymia Pause. Answer. **Keyed Letter**: C **Why It Is Correct**: Cyclothymic disorder is characterized by a chronic, fluctuating mood disturbance lasting at least 2 years in adults (1 year in children and adolescents) involving numerous periods of hypomanic symptoms and periods of depressive symptoms that do not meet full DSM-5-TR diagnostic thresholds for major depressive or hypomanic episodes. Jeremy's 15-year history of chronic low-level mood swings without severe functional impairment, hospitalization, or suicidal ideation fits cyclothymic disorder. **Why the Other Choices Are Wrong**: * **A**: Bipolar I disorder requires at least 1 full manic episode lasting at least 1 week or requiring hospitalization, which Jeremy explicitly denies. * **B**: Bipolar II disorder requires at least 1 fully validated major depressive episode lasting at least 2 weeks and at least 1 distinct hypomanic episode lasting at least 4 days. * **D**: Dysthymia (persistent depressive disorder) consists of chronic low-grade depressive symptoms lasting at least 2 years without any periods of hypomanic or manic symptom surges. Question 2. A PMHNP is evaluating a patient with a history of mood instability. The clinician recognizes that among all bipolar spectrum conditions, the patient who is most likely to be misdiagnosed as having unipolar major depressive disorder typically has which condition? A. Dysthymia B. Bipolar II disorder C. Bipolar I disorder D. Cyclothymic disorder Pause. Answer. **Keyed Letter**: B **Why It Is Correct**: Patients with Bipolar II disorder predominantly seek clinical treatment during major depressive episodes. They rarely present for care during hypomanic episodes because hypomania is typically experienced as a period of high energy, increased efficiency, and pleasant productivity. Unless the clinician specifically conducts a careful longitudinal assessment to uncover past hypomanic blips, Bipolar II is frequently misdiagnosed as unipolar major depressive disorder. **Why the Other Choices Are Wrong**: * **A**: Dysthymia is a primary unipolar depressive disorder characterized by chronic low-grade depression without any history of manic or hypomanic episodes. * **C**: Bipolar I disorder involves full manic episodes that cause severe occupational disruption, psychotic symptoms, or emergency hospitalization, making the manic history obvious rather than hidden. * **D**: Cyclothymic disorder consists of subthreshold mood fluctuations that do not meet full criteria for major depressive episodes, so patients do not present with classic unipolar major depression. What topic or chapter should we review next? Next. Topic. Sample Question 125: Differentiation. Bottom Line Summary. * Bipolar I disorder requires at least 1 manic or mixed episode, whereas Bipolar II disorder requires at least 1 major depressive episode and at least 1 hypomanic episode with zero history of mania. * Diagnostic criteria for a manic episode require abnormally elevated, expansive, or irritable mood and increased goal-directed activity lasting at least 1 week, or any duration if hospitalization is required, with 3 or more DIG FAST symptoms (4 if mood is only irritable). * Hypomania requires the same DIG FAST symptom cluster lasting at least 4 consecutive days, causing an unequivocal change in functioning noticed by others, but never causing marked social or occupational impairment, never requiring hospitalization, and never featuring psychosis. * Rapid cycling specifier is defined as 4 or more major mood episodes (major depressive, manic, or hypomanic) within a 12-month period, whereas mixed features involves meeting full criteria for mania or hypomania with at least 3 co-occurring depressive symptoms (or vice versa). * First-line acute mania agents include **lithium**, **valproate**, **carbamazepine**, or second-generation antipsychotics; **lithium** is preferred for classic euphoric mania, while **valproate** is preferred for dysphoric mania, mixed features, or comorbid substance use. * Acute bipolar depression is treated with **quetiapine** 300 mg daily, **lurasidone**, **lumateperone**, **lamotrigine**, **lithium**, or **olanzapine** with **fluoxetine**; antidepressant monotherapy is strictly avoided due to the risk of triggering mania or rapid cycling. * **Lithium** therapeutic trough level is 0.8 to 1.2 mEq/L for acute mania and 0.6 to 1.0 mEq/L for maintenance; toxicity begins around 1.5 mEq/L, and levels are elevated by NSAIDs, ACE inhibitors, ARBs, and thiazide diuretics. Bipolar Spectrum Criteria and Clinical Differentiation. Mania versus Hypomania. * Mood and activity: Both conditions require abnormally elevated, expansive, or irritable mood accompanied by persistently increased goal-directed activity or energy. * Timeline: Mania requires a duration of at least 1 week, unless hospitalization occurs sooner. Hypomania requires a duration of at least 4 consecutive days. * DIG FAST symptom cluster: Distractibility, Indiscretion or reckless spending/behavior, Grandiosity, Flight of ideas or racing thoughts, Activity increase or psychomotor agitation, Sleep deficit or decreased need for sleep, and Talkativeness or pressure to keep talking. Both episodes require 3 symptoms if mood is elevated or 4 symptoms if mood is only irritable. * Severity and safety: Mania causes marked impairment in social or occupational functioning, may necessitate hospitalization to prevent harm, or may feature psychotic symptoms. Hypomania causes a clear, noticeable change in functioning, but does not cause marked social or occupational impairment, does not require hospitalization, and never features psychosis. * Safety alert: If a patient with elevated mood presents with psychotic features or requires psychiatric hospitalization for safety, the episode is automatically classified as mania, confirming a diagnosis of **bipolar I disorder** regardless of symptom duration. Bipolar I, Bipolar II, and Cyclothymia. * **Bipolar I disorder**: Defined by the occurrence of at least 1 manic or mixed episode. Major depressive episodes occur in 90 percent of patients, but 10 percent experience manic episodes exclusively. * **Bipolar II disorder**: Defined by at least 1 major depressive episode and at least 1 hypomanic episode, with no history of a full manic episode. * Board trap: Patients with **bipolar II disorder** are frequently misdiagnosed with unipolar **major depressive disorder** because they seek treatment during distressing depressive phases and rarely report hypomanic periods, which feel pleasant, ego-syntonic, or highly productive. * **Cyclothymic disorder**: A chronic mood disturbance lasting at least 2 years in adults, or 1 year in children and adolescents, characterized by numerous periods of hypomanic symptoms and depressive symptoms that do not meet full criteria for hypomania or major depression. Symptoms are present for at least half the time, and the individual is never symptom-free for more than 2 months at a time. Course Specifiers: Rapid Cycling and Mixed Features. * Rapid cycling specifier: Applied when an individual experiences 4 or more distinct major mood episodes (major depressive, manic, or hypomanic) within a single 12-month period. * Mixed features specifier: Applied when full diagnostic criteria for a manic or hypomanic episode are met along with at least 3 co-occurring depressive symptoms, or when a major depressive episode presents with at least 3 manic or hypomanic symptoms. Psychopharmacology and Safety Parameters. * First-line acute mania management: **Divalproex**, **lithium**, **carbamazepine**, or second-generation antipsychotics. Second-generation antipsychotics demonstrate a faster onset of action for acute agitation and aggression compared to traditional mood stabilizers. * First-line acute bipolar depression: **Quetiapine**, **lurasidone**, **lumateperone**, **lamotrigine**, or **lithium**. * Safety alert: Antidepressant monotherapy is contraindicated in **bipolar disorder** because un-booted antidepressant use can precipitate acute mania or accelerate rapid cycling. Antidepressants should be tapered and discontinued if manic symptoms emerge. * First-line drug selection pearls: **Lithium** is the gold standard for classic euphoric mania and carries a proven independent protective effect against suicide. **Divalproex** is preferred for dysphoric or irritable mania, mixed features, comorbid substance use disorder, or prior **lithium** failure. * **Lithium** safety and laboratory monitoring: Therapeutic range is 0.8 to 1.2 mEq/L for acute mania and 0.6 to 1.0 mEq/L for maintenance. Trough levels are drawn 12 hours post-dose after 4 days of initiation. Baseline labs must include BUN, serum creatinine, GFR, TSH, serum electrolytes, CBC, pregnancy test (hCG), urinalysis, and a baseline EKG in patients over age 50. * Board trap: Co-administering NSAIDs such as **ibuprofen**, ACE inhibitors such as **lisinopril**, or thiazide diuretics with **lithium** decreases renal clearance and precipitates severe **lithium** toxicity. * **Valproate** laboratory monitoring: Therapeutic serum range is 50 to 120 mcg/mL. Baseline and periodic liver function tests (AST, ALT), CBC with differential and platelets, and pregnancy testing are required. Discontinue therapy if transaminases exceed 2 to 3 times the upper limit of normal. * **Carbamazepine** genetic safety: Requires mandatory screening for the HLA-B*1502 allele in patients of Asian ancestry prior to initiation due to high risk of **Stevens-Johnson syndrome**. * **Lamotrigine** clinical pearl: **Lamotrigine** does not require baseline laboratory monitoring, but requires slow dosage escalation starting at 25 mg daily to prevent life-threatening rashes. Fitzgerald Sample Questions. Question 4. Jeremy, a 36-year-old married attorney, was referred by his primary care provider for a consultation regarding his depression. He relates problems with what he calls minor depression and mood swings for at least 15 years. He denies ever having any suicidal ideation, hospitalization, or legal difficulty. On the Mood Disorder Questionnaire, he checks 4 items positive and 3 as possibly positive. Which disorder most likely fits his symptoms? A) Bipolar I disorder B) Bipolar II disorder C) Cyclothymic disorder D) Dysthymia Pause. Answer. C. Keyed letter: C. Why correct: Jeremy exhibits a 15-year history of chronic mild depressive symptoms and hypomanic mood swings that do not cause severe social or occupational impairment, hospitalization, or legal issues, which fits the criteria for **cyclothymic disorder** (at least 2 years of persistent hypomanic and depressive symptoms falling short of full criteria). Why the other choices are wrong: * A: **Bipolar I disorder** requires at least 1 full manic episode, which typically causes marked impairment, legal trouble, or hospitalization. * B: **Bipolar II disorder** requires at least 1 full major depressive episode lasting 2 weeks alongside a distinct hypomanic episode. * D: Dysthymia, or **persistent depressive disorder**, involves chronic low-grade depression without hypomanic mood swings. Question 5. The patient with bipolar disorder who is most likely to be misdiagnosed as having unipolar depression most likely has: A) Dysthymia B) Bipolar II disorder C) Bipolar I disorder D) Cyclothymia Pause. Answer. B. Keyed letter: B. Why correct: **Bipolar II disorder** is frequently misdiagnosed as unipolar **major depressive disorder** because patients seek clinical care during debilitating depressive episodes and rarely report hypomanic episodes, which are non-disruptive and feel pleasant or highly productive. Why the other choices are wrong: * A: Dysthymia is a unipolar depressive condition characterized by chronic low mood without manic or hypomanic episodes. * C: **Bipolar I disorder** includes overt manic episodes that cause severe functional disruption, psychosis, or hospitalization, making it easily distinguishable from unipolar depression. * D: **Cyclothymia** consists of chronic mild mood fluctuations that do not meet the full diagnostic criteria for a major depressive episode. Question 18. Mr. Cooper is treated for bipolar disorder with lithium carbonate. His last lithium level was 0.7 mEq/L. Which of the following is NOT a risk factor for developing lithium toxicity? A) Ibuprofen 600 mg daily for joint pain B) Addition of lisinopril to blood pressure regimen C) A change in GFR less than 60 mL/min D) Addition of prednisone for the management of an acute gout attack Pause. Answer. D. Keyed letter: D. Why correct: **Prednisone** is a corticosteroid that does not alter renal **lithium** clearance or elevate serum **lithium** concentrations, making it safe regarding **lithium** toxicity risk. Why the other choices are wrong: * A: **Ibuprofen** is an NSAID that reduces renal blood flow and **lithium** clearance, significantly elevating serum **lithium** levels. * B: **Lisinopril** is an ACE inhibitor that reduces **lithium** excretion through renal hemodynamic changes, creating a high risk of **lithium** toxicity. * C: A drop in GFR below 60 mL/min reflects impaired renal clearance, causing **lithium** accumulation and toxicity. Question 9. There is positive evidence that the use of lithium by a breastfeeding woman can pose a risk to the infant. This medication meets Hale's lactation risk category: A) L1 B) L2 C) L3 D) L4 Pause. Answer. D. Keyed letter: D. Why correct: **Lithium** is classified as Hale's Lactation Risk Category L4 because it is excreted into breast milk and poses substantial risks of infant toxicity, hypotonia, and fluid or electrolyte imbalances. Why the other choices are wrong: * A: Category L1 represents safest medications with extensive data showing no infant harm. * B: Category L2 represents safer medications with limited risk in controlled studies. * C: Category L3 represents moderately safe medications where risk to the infant is possible but benefits may outweigh risks. Question 20. Which of the following medications does not require initial laboratory testing before implementing therapy? A) Carbamazepine B) Lamotrigine C) Valproate D) Lithium Pause. Answer. B. Keyed letter: B. Why correct: **Lamotrigine** does not require baseline laboratory monitoring prior to initiation, relying instead on slow clinical dose titration to minimize the risk of **Stevens-Johnson syndrome**. Why the other choices are wrong: * A: **Carbamazepine** requires baseline complete blood count, liver function tests, and HLA-B*1502 genetic screening in patients of Asian descent. * C: **Valproate** requires baseline liver function tests, complete blood count with platelets, and pregnancy testing. * D: **Lithium** requires extensive baseline testing including renal function, thyroid function, electrolytes, CBC, urinalysis, pregnancy test, and EKG. 💡 Next, you might want to review Fitzgerald Chapter 8's section on acute psychopharmacotherapy for bipolar depression versus mania, or test your recall on the DIG FAST mnemonic and laboratory monitoring parameters. Next. End of this drive.